scispace - formally typeset
B

Barbara Dockhorn-Dworniczak

Researcher at University of Münster

Publications -  111
Citations -  5748

Barbara Dockhorn-Dworniczak is an academic researcher from University of Münster. The author has contributed to research in topics: Comparative genomic hybridization & Sarcoma. The author has an hindex of 41, co-authored 111 publications receiving 5607 citations. Previous affiliations of Barbara Dockhorn-Dworniczak include University of Pennsylvania & University of Düsseldorf.

Papers
More filters
Journal ArticleDOI

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.

TL;DR: Findings indicate that re-expression of caspase-8, e.g. by demethylation or casp enzyme-8 gene transfer, might be an effective strategy to restore sensitivity for chemotherapy- or death receptor-induced apoptosis in various tumors in vivo.
Journal ArticleDOI

Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86

TL;DR: Fifty-two percent of CESS 86 patients survived after risk-adapted therapy, and high-risk patients seem to have benefited from intensified treatment that incorporated ifosfamide, in multivariate analyses.
Journal ArticleDOI

Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.

TL;DR: Analysis of paraffin‐embedded specimens of DCIS and six associated invasive carcinomas revealed a genetic pattern almost identical to the one seen in the DCIS counterpart, characterize DCIS as a genetically far‐advanced, heterogeneous lesion and as a direct precursor of invasive breast cancer.
Journal ArticleDOI

Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies

TL;DR: Whole lung irradiation and megatherapy improve outcome in subgroups of patients with disseminated Ewing tumors is 0.27, and whole lung irradiated patients with combined pulmonary/skeletal metastases with combined lung plus bone/BM metastases improve outcome.
Journal ArticleDOI

Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor Patients

TL;DR: Results suggest a possible advantage in PFS for patients with localized disease and fusion type I transcripts, although this will require prospective validation with a larger number of patients and longer follow-up periods.